p16与粒细胞-巨噬细胞集落刺激因子联合基因疗法治疗小鼠肾癌的研究

目的 探讨瘤体内直接注射途径的Ｐ１６抑癌基因疗法与粒细胞－巨噬细胞落刺激因子（ＧＭ－ＣＳＦ）的基因疗法联合应用对小鼠肾癌（ｒｅｎｅａ）的治疗效果及其免疫学机理。方法 建立皮下荷瘤肾癌小鼠模型，干接种肿瘤细胞３天后将荷瘤小鼠随机分为５组，分别给予不同的治疗，检测每组小鼠的免疫功能，观察每组小 的存活期，并行肿瘤病理学分析。结果 Ａｄｐ１６＋ＡｄＧＭ－ＣＳＦ联合治疗组有２只长期存活（存活时间〉９０ｄ）

Study on antitumor effects of p16 and granulocyte macrophage-colony stimulating factor combined gene therapy for renal carcinoma

Objective\ To investigate the antitumor effects of p16 and GM CSF combined gene therapy for renal cell carcinoma (renca) and elucidate the immune mechanisms of its antitumor response. Methods\ The model of renal tumor bearing mice by injected subcutaneously was developed. The tumor bearing mice were grouped as 5 groups at random 3 days after injection of Renca cells. Different groups of the mice were subjected to different treatments. The antitumor immune responses and the survival time of the mice were tested. Histopathologic analysis of tumor tissue was performed. Results\ The mice receiving combined therapy of AdP16 AdGM CSF were able to survive much longer than all the other mice receiving control therapies ( P <0.01). Two of 10 mice after AdP16/AdGM CSF combined therapy were found to be tumor free and lived more than 90 days, while the control animals died within 52 days. Enhancement of the NK cytotoxicity (33%) were observed more obviously in tumor bearing mice after combined therapy when compared with that of the other 4 groups ( P <0.01). Conclusion\ p16 and GM CSF combined gene therapy can enhance the antitumor immune responses of mice and inhibit the growth of pre established renal cell carcinoma, also prolong the survival time of tumor bearing mice.